Evidence · Randomised trial
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
- Communicating with families
- Families and professional practice
- Infection
- Infection prevention
- Medical
- Nursing
- Postnatal and transitional care
Summary
Investigator-blind randomised controlled trial in Entebbe, Uganda, comparing BCG vaccination on the day of birth with vaccination at 6 weeks in healthy infants well enough for discharge from the labour ward. BCG at birth was associated with lower physician-diagnosed non-tuberculous infectious disease in the first 6 weeks of life. The trial also explored trained innate immunity mechanisms, including histone modification at cytokine gene promoters, cytokine responses and iron markers. The authors suggest prioritising BCG on the first day of life in high-mortality settings.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.